|Price and Volume|
|52 Week High||314.88|
|52 Week Low||90.00|
|Avg. Daily Vol. (Mil)||0.57|
|Beta (3 year)||-8.08|
|Share Related Items|
|Mkt Cap (Mil)||2,280.11|
|Shares Out (Mil)||24.33|
|LT Debt/ Equity||0.00|
|Total Debt / Equity||0.00|
|Per Share Data|
|Intercept Pharmaceuticals Inc is a biopharmaceutical company. The Company is engaged in the development and commercialization of novel therapeutics to treat chronic liver disease utilizing its proprietary bile acid chemistry.|
|450 West 15th Street
New York, NY 10011
|Industry : Drugs|
|Sector: Health Care|
|CEO: Mr. Mark Pruzanski, M.D.|
|Current Month (Mil)||3.24|
|Previous Month (Mil)||3.10|
|Short Interest Ratio (Days)||6.10|
|Return on Equity||n.a.|
|Return on Assets||-24.10|
|Return on Investments||-25.50|
Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.
David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
Every recommendation goes through 3 layers of intense scrutinyquantitative, fundamental and technical analysisto maximize profit potential and minimize risk.
More than 30 investing pros with skin in the game give you actionable insight and investment ideas.
|Rating||Current||1-Mo Ago||2-Mo Ago||3-Mo Ago|
|GET ICPT ANALYST REPORT|